当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Does antiviral therapy prevent hepatocellular carcinoma?

Does antiviral therapy prevent hepatocellular carcinoma?

Abstract：

:Chronic infection with HBV or HCV can lead to the development of hepatocellular carcinoma (HCC). The major risk factors for HBV-related HCC are persistent presence of hepatitis B e antigen (HBeAg) and/or high serum HBV DNA levels, and cirrhosis. The major risk factor for HCV-related HCC is cirrhosis. One randomized double blind controlled trial of lamivudine in patients with HBeAg and/or high serum HBV DNA levels showed that antiviral therapy prevented disease progression and reduced the incidence of HCC. A beneficial effect of antiviral therapy on the risk of HCC has also been shown in cohort studies and meta-analyses, particularly among responders. Several randomized controlled trials of interferon in patients with HCV-related cirrhosis showed that treated patients had a lower incidence of HCC. A greater effect was observed in patients who achieved sustained virological response, while the benefit in non-responders is unclear. Antiviral therapies for hepatitis B and hepatitis C can prevent but not completely eliminate HCC. Improvement in identification of infected persons, accessibility of care and affordability of treatment is needed for antiviral therapy to have a major impact on the global incidence of HCC.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Kwon H,Lok AS

doi

10.3851/IMP1895

subject

Has Abstract

pub_date

2011-01-01 00:00:00

pages

787-95

issue

6

eissn

1359-6535

issn

2040-2058

journal_volume

16

pub_type

杂志文章,评审

相关文献

ANTIVIRAL THERAPY文献大全
  • Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.

    abstract：BACKGROUND:Regulatory T-cells (Treg) hamper immune responses elicited by cancer vaccines. Therefore, depletion of Treg is being used to improve the outcome of vaccinations. METHODS:We studied whether an alphavirus vector-based immunotherapeutic vaccine changes the number and/or activity of Treg and if Treg depletion i...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1751

    authors： Walczak M,Regts J,van Oosterhout AJ,Boon L,Wilschut J,Nijman HW,Daemen T

    更新日期：2011-01-01 00:00:00

  • Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

    abstract：OBJECTIVES:To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg). DESIGN:Two-parallel groups, addition of LPV in patients receiving ATV (n=6), and addition of ATV in patients receiving LPV (n=...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Colombo S,Buclin T,Franc C,Guignard N,Khonkarly M,Tarr PE,Rochat B,Biollaz J,Telenti A,Decosterd LA,Cavassini M

    更新日期：2006-01-01 00:00:00

  • Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).

    abstract：BACKGROUND:Although thiazolidinediones have been shown to increase subcutaneous fat in congenital lipodystrophy, rosiglitazone did not show convincing results in HIV lipoatrophy. We assess a potential specific effect of pioglitazone in this setting. METHODS:One-hundred and thirty HIV-1-infected adults with self-report...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：

    authors： Slama L,Lanoy E,Valantin MA,Bastard JP,Chermak A,Boutekatjirt A,William-Faltaos D,Billaud E,Molina JM,Capeau J,Costagliola D,Rozenbaum W

    更新日期：2008-01-01 00:00:00

  • Zidovudine treatment is not associated with HTLV-1 reverse transcriptase gene mutations in HTLV-I/HIV-1 co-infected patients.

    abstract：:Zidovudine treatment of human immunodeficiency virus (HIV) infection induces drug-resistant viral strains harbouring specific amino acid substitutions in the reverse transcriptase (RT). To investigate whether this phenomenon could be observed in the case of human T lymphotropic virus type I (HTLV-I) infection, we anal...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Gasmi M,Fillon S,Leriche K,Neisson-Vernant C,Desgranges C

    更新日期：1997-04-01 00:00:00

  • Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.

    abstract：BACKGROUND:The potential use of variola virus as a biological weapon has renewed efforts in the development of antiviral agents against orthopoxviruses. ST-246 [4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide] is an anti-orthopoxvirus compound active ag...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Duraffour S,Snoeck R,de Vos R,van Den Oord JJ,Crance JM,Garin D,Hruby DE,Jordan R,De Clercq E,Andrei G

    更新日期：2007-01-01 00:00:00

  • The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.

    abstract：BACKGROUND:Current stopping rules during pegylated interferon (peg-IFN)/ribavirin (RBV) treatment rely on week 12 HCV RNA response, but earlier identification of non-responders offers clinical and economic advantages. AIMS AND METHODS:To evaluate, among 129 HCV-genotype-1-infected, treatment-naive patients receiving p...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Bárcena R,Moreno A,del Campo S,Muriel A,Mateos ML,Garrido E,García M,Quereda C,Moreno S,Moreno A

    更新日期：2007-01-01 00:00:00

  • Hepatitis C coinfection enhances sensitization of CD4(+) T-cells towards Fas-induced apoptosis in viraemic and HAART-controlled HIV-1-positive patients.

    abstract：BACKGROUND:Recently, we identified increased rates of CD4(+) T-cell apoptosis in HCV-infected HIV-positive patients as a potential mechanism for enhanced mortality in patients with HIV/HCV coinfection. Since this effect might be attributed to changes in receptor-induced apoptosis, we studied expression and function of ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1882

    authors： Körner C,Tolksdorf F,Riesner K,Krämer B,Schulte D,Nattermann J,Rockstroh JK,Spengler U

    更新日期：2011-01-01 00:00:00

  • Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.

    abstract：INTRODUCTION:Patients with hepatitis C recurrence after liver transplantation represent a clinical challenge. Antiviral treatment in transplant patients has usually poor tolerability and limited efficacy, with a mean sustained virological response (SVR) of 30%. Our pilot study was aimed at evaluating whether 8-week rib...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1834

    authors： Merli M,Giannelli V,Gentili F,Giusto M,Simmaco M,Lionetto L,Corradini SG,Biliotti E,Attili AF,Rossi M,Taliani G

    更新日期：2011-01-01 00:00:00

  • Factors associated with non-adherence to HBV antiviral therapy.

    abstract：BACKGROUND:HBV antiviral therapy has the potential to reduce the burden of HBV-related liver disease by suppressing HBV DNA replication to undetectable levels, reducing the progression of liver fibrosis and reducing the risk of hepatocellular carcinoma (HCC) development. Treatment outcomes and long-term benefits requir...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP3219

    authors： Sheppard-Law S,Zablotska-Manos I,Kermeen M,Holdaway S,Lee A,George J,Zekry A,Maher L

    更新日期：2018-01-01 00:00:00

  • Smoking motivations and quitting motivations among HIV-infected smokers.

    abstract：BACKGROUND:The aim of this study was to examine smoking motivation and motivation to quit, and determinants of these motivations among HIV-infected cigarette smokers. METHODS:We conducted a 1-day cross-sectional survey on cigarette smoking in a representative sample of HIV-infected outpatients of French hospitals. A c...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1292

    authors： Peretti-Watel P,Garelik D,Baron G,Spire B,Ravaud P,Duval X,EVIT Study Group.

    更新日期：2009-01-01 00:00:00

  • Cidofovir does not prevent caprine herpesvirus type-1 neural latency in goats.

    abstract：BACKGROUND:Cidofovir (CDV) is an acyclic nucleoside phosphonate that exhibits a potent antiviral activity against several DNA viruses. In previous studies, CDV has been shown to significantly reduce the clinical severity and the viral shedding in primary caprine herpesvirus type-1 (CpHV-1) infection in goats. CpHV-1 is...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1611

    authors： Camero M,Crescenzo G,Marinaro M,Tarsitano E,Bellacicco AL,Armenise C,Buonavoglia C,Tempesta M

    更新日期：2010-01-01 00:00:00

  • Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.

    abstract：BACKGROUND:Rilpivirine-based regimens are now preferred or alternative first-line regimens according to many HIV treatment guidelines. Recently, a surveillance study conducted in Argentina determined that prevalence of pretreatment resistance to first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3147

    authors： Bissio E,Barbás MG,Kademián S,Bouzas MB,Salomón H,Cudolá A,Giuliano SF,Falistocco C

    更新日期：2017-01-01 00:00:00

  • Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

    abstract：BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：10.3851/IMP2358

    authors： Vingerhoets J,Rimsky L,Van Eygen V,Nijs S,Vanveggel S,Boven K,Picchio G

    更新日期：2013-01-01 00:00:00

  • Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.

    abstract：BACKGROUND:In China, the optimal management of individuals living with chronic HBV infection remains an unmet need. The EVOLVE was a 5-year prospective, longitudinal, observational study that compared the clinical outcomes in treatment-naïve CHB patients receiving entecavir (ETV) or lamivudine (LAM)-based therapies. M...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3372

    authors： Jia J,Shang J,Tang H,Jiang J,Ning Q,Dou X,Zhang S,Zhang M,Han T,Tan D,Zhou X,Chen G,Sheng J,Su Z,Chen H,Dai E,Ye Y,Guo Y,Shen Y,Yuan J,Wei Z,Zhu S,EVOLVE Study Group.

    更新日期：2020-10-22 00:00:00

  • Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.

    abstract：BACKGROUND:Suboptimal doses of ribavirin have been suggested to explain the diminished efficacy of pegylated interferon (PEG-IFN) plus ribavirin in hepatitis C virus (HCV)-HIV-coinfected patients. METHODS:A cohort of 104 coinfected patients and an age-, sex- and genotype-matched cohort of HCV-monoinfected patients (n ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Tural C,Galeras JA,Planas R,Coll S,Sirera G,Giménez D,Salas A,Rey-Joly C,Cirera I,Márquez C,Tor J,Videla S,García-Retortillo M,Clotet B,Solà R

    更新日期：2008-01-01 00:00:00

  • Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.

    abstract：:Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased respo...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1671

    authors： Llibre JM

    更新日期：2010-01-01 00:00:00

  • A light in the cognitive fog?

    abstract：:HIV escape in the central nervous system (CNS) despite undetectable viral load in the plasma has been observed and may contribute to HIV-associated neurocognitive disorders. Favouring the use of HIV drugs with a good penetration into the CNS has been advocated, leading to the establishment of the CNS penetration-effec...

    journal_title：Antiviral therapy

    pub_type： 评论,杂志文章

    doi：10.3851/IMP2561

    authors： Cavassini M,Du Pasquier RA

    更新日期：2013-01-01 00:00:00

  • Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.

    abstract：OBJECTIVE:The aim of the study was to analyse the response to highly active antiretroviral therapy (HAART) initiated at the time of primary HIV infection (PHI) in patients infected with a virus resistant to > or = 1 drug of their treatment compared with patients infected with a wild-type virus. METHODS:We analysed dat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Chaix ML,Desquilbet L,Descamps D,Costagliola D,Deveau C,Galimand J,Goujard C,Signori-Schmuck A,Schneider V,Tamalet C,Pellegrin I,Wirden M,Masquelier B,Brun-Vezinet F,Rouzioux C,Meyer L,French PRIMO Cohort Study Group (ANR

    更新日期：2007-01-01 00:00:00

  • Acute renal failure related to high doses of acyclovir (15 mg/kg/8 h) during treatment of varicella zoster virus encephalitis.

    abstract：:Varicella zoster virus (VZV) is less susceptible than herpes simplex virus to acyclovir. The optimal acyclovir regimen during VZV encephalitis remains unknown. We report two cases of acute renal failure after an increase in acyclovir dosage from 10 mg to 15 mg/kg/8 h during the treatment of VZV encephalitis according ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3313

    authors： Martinot M,Klein A,Demesmay K,Groza M,Mohseni-Zadeh M,Tebacher-Alt M,Fafi-Kremer S

    更新日期：2019-01-01 00:00:00

  • Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

    abstract：BACKGROUND:Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS:Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Vogel M,Nattermann J,Baumgarten A,Klausen G,Bieniek B,Schewe K,Jessen H,Boesecke C,Rausch M,Lutz T,Fenske S,Schranzo D,Kümmerle T,Schuler C,Theisen A,Mayr C,Seidel T,Rockstroh JK

    更新日期：2006-01-01 00:00:00

  • Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.

    abstract：BACKGROUND:Alternatives to the available stavudine-containing paediatric fixed-dose combination (FDC) tablets are rapidly needed due to concerns regarding the cumulative toxicity of long-term stavudine exposure. We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lam...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.3851/IMP1931

    authors： Chokephaibulkit K,Cressey TR,Capparelli E,Sirisanthana V,Muresan P,Hongsiriwon S,Ngampiyaskul C,Limwongse C,Wittawatmongkol O,Aurpibul L,Kabat B,Toye M,Smith ME,Eksaengsri A,McIntosh K,Yogev R,IMPAACT P1069 Team.

    更新日期：2011-01-01 00:00:00

  • Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.

    abstract：BACKGROUND:US guidelines recommend genotyping for persons newly diagnosed with HIV infection to identify transmitted drug resistance mutations associated with decreased susceptibility to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors. To date, testin...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2780

    authors： Stekler JD,McKernan J,Milne R,Tapia KA,Mykhalchenko K,Holte S,Maenza J,Stevens CE,Buskin SE,Mullins JI,Frenkel LM,Collier AC

    更新日期：2015-01-01 00:00:00

  • Principles of HIV resistance testing and overview of assay performance characteristics.

    abstract：:HIV drug resistance testing is becoming an integral part of antiretroviral drug development and of patient management. The parameters that characterize the performance of both phenotypic and genotypic assays and the validation of this performance are essential to their proper use for these applications. Several princi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Richman DD

    更新日期：2000-03-01 00:00:00

  • Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection.

    abstract：OBJECTIVE:In patients with a chronic asymptomatic HIV-1 infection and >200 CD4+ T-cells/microl, the optimal timing of highly active antiretroviral therapy (HAART) initiation is unclear. It involves a trade-off between a potentially reduced risk of mortality, when started earlier in the course of infection, and an earli...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Locadia M,van Grieken RA,Prins JM,de Vries HJ,Sprangers MA,Nieuwkerk PT

    更新日期：2006-01-01 00:00:00

  • Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.

    abstract：BACKGROUND:We examined whether waist circumference (WC) and self-reported abdominal size changes can estimate visceral adipose tissue (VAT) changes for those initiating antiretroviral therapy (ART). METHODS:Prospectively collected data from ACTG A5257 and its metabolic substudy, A5260s, were used for this analysis. AR...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3148

    authors： Bhagwat P,Ofotokun I,McComsey GA,Brown TT,Moser C,Sugar CA,Currier JS

    更新日期：2017-01-01 00:00:00

  • Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group.

    abstract：:Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy was initiated prior to laboratory confirmation of hantavirus infection because most deaths from H...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Chapman LE,Mertz GJ,Peters CJ,Jolson HM,Khan AS,Ksiazek TG,Koster FT,Baum KF,Rollin PE,Pavia AT,Holman RC,Christenson JC,Rubin PJ,Behrman RE,Bell LJ,Simpson GL,Sadek RF

    更新日期：1999-01-01 00:00:00

  • In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin.

    abstract：BACKGROUND:Zika virus, a previously neglected mosquito-borne virus, is prompting worldwide concern because of its connection with congenital defects, Guillain-Barré syndrome, meningoencephalitis and myelitis in infected individuals. However, no specific antiviral therapy is available at present. In this study, we inves...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3180

    authors： Baz M,Goyette N,Griffin BD,Kobinger GP,Boivin G

    更新日期：2017-01-01 00:00:00

  • The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.

    abstract：BACKGROUND:Nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) cause side effects in some patients, prompting the use of either partly or fully NRTI-sparing regimens. METHODS:We used data from the Swiss HIV Cohort Study to estimate the effectiveness of two new dolutegravir dual regimens relative to the...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3310

    authors： Young J,Scherrer AU,Calmy A,Tarr PE,Bernasconi E,Cavassini M,Hachfeld A,Vernazza P,Günthard HF,Bucher HC,Swiss HIV Cohort Study.

    更新日期：2019-01-01 00:00:00

  • Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.

    abstract：OBJECTIVES:To characterize 1-year virological response to antiretroviral therapy and its determinants by sex. METHODS:This is a population-based analysis of antiretroviral therapy naive HIV-positive adult men and women. Factors associated with sex and with plasma HIV RNA viral load suppression to below 500 copies/ml w...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： O'Connell JM,Braitstein P,Hogg RS,Yip B,Craib KJ,O'Shaughnessy MV,Montaner JS,Burdge DR

    更新日期：2003-12-01 00:00:00

  • Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.

    abstract：:Cytomegalovirus (CMV) remains a leading cause of morbidity after solid organ transplantation. The efficiency of antivirals for the treatment of CMV infections may be hampered because of the emergence of CMV resistance to antivirals. The development of CMV multidrug resistance, which remains uncommon but does occur, co...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2818

    authors： Deback C,Burrel S,Varnous S,Carcelain G,Conan F,Aït-Arkoub Z,Autran B,Gandjbakhch I,Agut H,Boutolleau D

    更新日期：2015-01-01 00:00:00